TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05731479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diathermy + exercise group
Description: The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diathermy placebo + exercise group
Description: The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
Study: NCT05454657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback + treatment as usual
Description: Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual only
Description: Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual only
Description: Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
Study: NCT05950984

Intervention type: OTHER
Intervention: Drug Infusion Pump Monitoring
Description: Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
Study: NCT05472883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood samples
Description: - Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collection of body tissues
Description: removal of intra-abdominal fat and muscle tissue
Study: NCT04890054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test
Description: Patients due for CRC screening are mailed a FIT test by the clinic or health plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test
Description: Patients due for CRC screening are mailed a FIT test by the clinic or health plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
Study: NCT05211206

Intervention type: OTHER
Intervention: IV fluids
Description: Amount of intravenous fluids delivered

Intervention type: OTHER
Intervention: IV fluids
Description: Amount of intravenous fluids delivered
Study: NCT06716632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Ligasure for heamostasis
Description: Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of conventional knot tying technique for heamostasis
Description: Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers. While these techniques effectively control bleeding from vessels, they are time-consuming and carry the risk of harming adjacent structures like the recurrent and superior laryngeal nerves.
Study: NCT04685564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the same as RBD1016
Study: NCT06290310

Intervention type: DEVICE
Intervention: EIT
Description: continuous electric impedance tomography measurement

Intervention type: DEVICE
Intervention: patient-ventilator asynchrony assessment
Description: patient-ventilator asynchrony assessment by flow/time curve and machine learning
Study: NCT05437289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IM
Description: In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IM
Description: In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IV
Description: In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442 IV
Description: In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
Study: NCT06182358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution, 0.25%
Description: XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Vehicle of XDEMVY administered topically twice a day for approximately 43 days
Study: NCT05324163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002 Spray
Description: X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
Study: NCT05691231

Intervention type: DEVICE
Intervention: NuVasive Simplify Cervical Artificial Disc
Description: Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
Study: NCT05472883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine care procedure
Description: * Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens.
Study: NCT06704516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy
Description: Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)
Study: NCT06713746

Intervention type: DIAGNOSTIC_TEST
Intervention: growth differentiation factor 15
Description: rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
Study: NCT06713967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage)
Description: In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
Study: NCT04748926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: caplet Route of administration: oral
Study: NCT06713967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (Diet and Exercise Only)
Description: In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
Study: NCT06722703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shock wave lithotripsy
Description: Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscope lithotripsy
Description: All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
Study: NCT04804709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat 15 MG
Description: After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound with neuro-navigator-controlled sonication
Description: The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed.
Study: NCT06156254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)
Description: Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
Study: NCT04748926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: caplet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
Study: NCT06511102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPT Support
Description: The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
Study: NCT04748926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib SAR444671
Description: Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
Study: NCT06383507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHT101
Description: After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
Study: NCT05959837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Rowing Exercise
Description: Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
Study: NCT05602961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-COV2-043
Description: COVID-19 vaccine, administered as a booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-COV2-043
Description: COVID-19 vaccine, administered as a booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-COV2-043
Description: COVID-19 vaccine, administered as a booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-COV2-043
Description: COVID-19 vaccine, administered as a booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2/COMIRNATY®
Description: active control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2/COMIRNATY®
Description: active control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2/COMIRNATY®
Description: active control
Study: NCT06724484

Intervention type: PROCEDURE
Intervention: Surgical management of fracture
Description: Surgical management of fracture

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06715397

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06723106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY121
Description: Injection
Study: NCT06724549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BN104
Description: This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BN104
Description: This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
Study: NCT06724107

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: UVC
Description: It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVC
Description: It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
Study: NCT06722885

Intervention type: RADIATION
Intervention: Standard radiotherapy treatment
Description: * 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases

Intervention type: RADIATION
Intervention: Standard radiotherapy treatment
Description: * 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases

Intervention type: RADIATION
Intervention: Standard radiotherapy treatment
Description: * 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases
Study: NCT06722027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Centered Spiritual Health Team Intervention (CCSH-TI)
Description: Delivered to healthcare teams by spiritual health clinicians proficient in group facilitation. It is composed of 4 sessions delivered every other week and lasting 60 minutes each.~CCSH-TI sessions teach participants to attune to their interpersonal relationships; acknowledge and allow difficult emotions; and access compassion. It also provides psychoeducation about skillful coping strategies. Each session consists of didactic material about team norms and safety, a feeling check-in, facilitated group discussions about social connection and professional team building, and meditations to promote mindfulness, to cultivate a feeling of being nurtured, and to access compassion for self and others. CCSH-TI is delivered to healthcare teams by spiritual health clinicians proficient in group facilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU refers to the current buffet of wellness and professional development activities that are available to employees at the Winship Cancer Institute.